Article Type
Article
Changed
Mon, 04/21/2025 - 11:24
Display Headline

Racial Disparities, Germline Testing, and Improved Overall Survival in Prostate Cancer

Author(s)
Michael Goodman, MD

Click here to view more from Cancer Data Trends 2025.

References

References

  1. Lillard JW Jr, Moses KA, Mahal BA, George DJ. Racial disparities in Black men with prostate cancer: A literature review. Cancer. 2022 Nov 1;128(21):3787-3795. doi:10.1002/cncr.34433

  2. Wang BR, Chen Y-A, Kao W-H, Lai C-H, Lin H, Hsieh J-T. Developing New Treatment Options for Castration-Resistant Prostate Cancer and Recurrent Disease. Biomedicines. 2022 Aug 3;10(8):1872. doi:10.3390/biomedicines10081872

  3. Valle LF, Li J, Desai H, Hausler R, et al. Oncogenic Alterations, Race, and Survival in US Veterans with Metastatic Prostate Cancer Undergoing Somatic Tumor Next Generation Sequencing. bioRxiv [Preprint]. 2024 Oct 25:2024.10.24.620071. doi:10.1101/2024.10.24.620071

  4. Kwon DH, Scheuner MT, McPhaul M, et al. Germline testing for veterans with advanced prostate cancer: concerns about service-connected benefits. JNCI Cancer Spectr. 2024 Sep 2;8(5):pkae079. doi:10.1093/jncics/pkae079

  5. Kwon DH, McPhaul M, Sumra S, et al. Informed decision-making about germline testing among Veterans with advanced prostate cancer (APC): A mixed-methods study. J Clin Oncol. 2024;42(16_suppl):5105. doi:10.1200/JCO.2024.42.16_suppl.5105

  6. Schoen MW, Montgomery RB, Owens L, Khan S, Sanfilippo KM, Etzioni RB. Survival in Patients With De Novo Metastatic Prostate Cancer. JAMA Netw Open. 2024 Mar 4;7(3):e241970. doi: 10.1001/jamanetworkopen.2024.1970

  7. Schafer EJ, Jemal A, Wiese D, et al. Disparities and Trends in Genitourinary Cancer Incidence and Mortality in the USA. Eur Urol. 2023 Jul;84(1):117-126. doi:10.1016/j.eururo.2022.11.023                    

  8. U.S. Department of Veterans Affairs. Hines VA Hospital & Loyola University Chicago Physician Awarded $8.6M VA Research Grant. November 8, 2021. https://www.va.gov/hines-health-care/news-releases/hines-va-hospital-loyola-university-chicago-physician-awarded-86m-va-research-grant/ Accessed December 31, 2024.                                                                                                            

  9. U.S. Department of Veterans Affairs. National Oncology Program. How VA is Advancing Prostate Cancer Care. https://www.cancer.va.gov/prostate.html Accessed December 31, 2024.

 

 

 

 

 

Author and Disclosure Information

Michael M. Goodman, MD
Associate Professor, Department of Hematology and Oncology
Atrium Health Wake Forest Baptist
Winston-Salem, North Carolina;
VA Hematology/Oncology Physician and Program Manager
Director, Salisbury VA Infusion Center
Salisbury, North Carolina

Dr. Goodman has disclosed no relevant financial relationships.

Publications
Federal Practitioner
Topics
Prostate Cancer
Author(s)
Michael Goodman, MD
Author(s)
Michael Goodman, MD
Author and Disclosure Information

Michael M. Goodman, MD
Associate Professor, Department of Hematology and Oncology
Atrium Health Wake Forest Baptist
Winston-Salem, North Carolina;
VA Hematology/Oncology Physician and Program Manager
Director, Salisbury VA Infusion Center
Salisbury, North Carolina

Dr. Goodman has disclosed no relevant financial relationships.

Author and Disclosure Information

Michael M. Goodman, MD
Associate Professor, Department of Hematology and Oncology
Atrium Health Wake Forest Baptist
Winston-Salem, North Carolina;
VA Hematology/Oncology Physician and Program Manager
Director, Salisbury VA Infusion Center
Salisbury, North Carolina

Dr. Goodman has disclosed no relevant financial relationships.

Click here to view more from Cancer Data Trends 2025.

Click here to view more from Cancer Data Trends 2025.

References

References

  1. Lillard JW Jr, Moses KA, Mahal BA, George DJ. Racial disparities in Black men with prostate cancer: A literature review. Cancer. 2022 Nov 1;128(21):3787-3795. doi:10.1002/cncr.34433

  2. Wang BR, Chen Y-A, Kao W-H, Lai C-H, Lin H, Hsieh J-T. Developing New Treatment Options for Castration-Resistant Prostate Cancer and Recurrent Disease. Biomedicines. 2022 Aug 3;10(8):1872. doi:10.3390/biomedicines10081872

  3. Valle LF, Li J, Desai H, Hausler R, et al. Oncogenic Alterations, Race, and Survival in US Veterans with Metastatic Prostate Cancer Undergoing Somatic Tumor Next Generation Sequencing. bioRxiv [Preprint]. 2024 Oct 25:2024.10.24.620071. doi:10.1101/2024.10.24.620071

  4. Kwon DH, Scheuner MT, McPhaul M, et al. Germline testing for veterans with advanced prostate cancer: concerns about service-connected benefits. JNCI Cancer Spectr. 2024 Sep 2;8(5):pkae079. doi:10.1093/jncics/pkae079

  5. Kwon DH, McPhaul M, Sumra S, et al. Informed decision-making about germline testing among Veterans with advanced prostate cancer (APC): A mixed-methods study. J Clin Oncol. 2024;42(16_suppl):5105. doi:10.1200/JCO.2024.42.16_suppl.5105

  6. Schoen MW, Montgomery RB, Owens L, Khan S, Sanfilippo KM, Etzioni RB. Survival in Patients With De Novo Metastatic Prostate Cancer. JAMA Netw Open. 2024 Mar 4;7(3):e241970. doi: 10.1001/jamanetworkopen.2024.1970

  7. Schafer EJ, Jemal A, Wiese D, et al. Disparities and Trends in Genitourinary Cancer Incidence and Mortality in the USA. Eur Urol. 2023 Jul;84(1):117-126. doi:10.1016/j.eururo.2022.11.023                    

  8. U.S. Department of Veterans Affairs. Hines VA Hospital & Loyola University Chicago Physician Awarded $8.6M VA Research Grant. November 8, 2021. https://www.va.gov/hines-health-care/news-releases/hines-va-hospital-loyola-university-chicago-physician-awarded-86m-va-research-grant/ Accessed December 31, 2024.                                                                                                            

  9. U.S. Department of Veterans Affairs. National Oncology Program. How VA is Advancing Prostate Cancer Care. https://www.cancer.va.gov/prostate.html Accessed December 31, 2024.

 

 

 

 

 

References

References

  1. Lillard JW Jr, Moses KA, Mahal BA, George DJ. Racial disparities in Black men with prostate cancer: A literature review. Cancer. 2022 Nov 1;128(21):3787-3795. doi:10.1002/cncr.34433

  2. Wang BR, Chen Y-A, Kao W-H, Lai C-H, Lin H, Hsieh J-T. Developing New Treatment Options for Castration-Resistant Prostate Cancer and Recurrent Disease. Biomedicines. 2022 Aug 3;10(8):1872. doi:10.3390/biomedicines10081872

  3. Valle LF, Li J, Desai H, Hausler R, et al. Oncogenic Alterations, Race, and Survival in US Veterans with Metastatic Prostate Cancer Undergoing Somatic Tumor Next Generation Sequencing. bioRxiv [Preprint]. 2024 Oct 25:2024.10.24.620071. doi:10.1101/2024.10.24.620071

  4. Kwon DH, Scheuner MT, McPhaul M, et al. Germline testing for veterans with advanced prostate cancer: concerns about service-connected benefits. JNCI Cancer Spectr. 2024 Sep 2;8(5):pkae079. doi:10.1093/jncics/pkae079

  5. Kwon DH, McPhaul M, Sumra S, et al. Informed decision-making about germline testing among Veterans with advanced prostate cancer (APC): A mixed-methods study. J Clin Oncol. 2024;42(16_suppl):5105. doi:10.1200/JCO.2024.42.16_suppl.5105

  6. Schoen MW, Montgomery RB, Owens L, Khan S, Sanfilippo KM, Etzioni RB. Survival in Patients With De Novo Metastatic Prostate Cancer. JAMA Netw Open. 2024 Mar 4;7(3):e241970. doi: 10.1001/jamanetworkopen.2024.1970

  7. Schafer EJ, Jemal A, Wiese D, et al. Disparities and Trends in Genitourinary Cancer Incidence and Mortality in the USA. Eur Urol. 2023 Jul;84(1):117-126. doi:10.1016/j.eururo.2022.11.023                    

  8. U.S. Department of Veterans Affairs. Hines VA Hospital & Loyola University Chicago Physician Awarded $8.6M VA Research Grant. November 8, 2021. https://www.va.gov/hines-health-care/news-releases/hines-va-hospital-loyola-university-chicago-physician-awarded-86m-va-research-grant/ Accessed December 31, 2024.                                                                                                            

  9. U.S. Department of Veterans Affairs. National Oncology Program. How VA is Advancing Prostate Cancer Care. https://www.cancer.va.gov/prostate.html Accessed December 31, 2024.

 

 

 

 

 

Publications
Federal Practitioner
Publications
Federal Practitioner
Topics
Prostate Cancer
Article Type
Article
Display Headline

Racial Disparities, Germline Testing, and Improved Overall Survival in Prostate Cancer

Display Headline

Racial Disparities, Germline Testing, and Improved Overall Survival in Prostate Cancer

Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Eyebrow Default
SLIDESHOW
Gate On Date
Sun, 04/06/2025 - 17:18
Un-Gate On Date
Sun, 04/06/2025 - 17:18
Use ProPublica
CFC Schedule Remove Status
Sun, 04/06/2025 - 17:18
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Article Slideshow Optional Introduction

The incidence of prostate cancer (PCa) has been rising1; this increase is particularly evident in more aggressive, advanced stages of PCa. Metastatic castration-resistant PCa has a median overall survival (OS) of up to about 2 years and is the second leading cause of cancer-related deaths among men in the United States.2

Black men face a significantly higher risk for PCa compared with White men.1 Researchers have identified variations in the genomic profiles of metastatic PCa cells among US veterans that are potentially linked to race and ethnicity. Study findings represent a significant advancement in understanding genomic alterations in metastatic prostate cancer.1 This is especially noteworthy for Black men, who have been historically underrepresented in precision oncology research.3

A qualitative study of veterans with advanced PCa explored decision-making regarding germline testing. Several veterans with service-connected disability benefits declined testing, fearing it might jeopardize their benefits.4,5 Consequently, language in the veterans benefits manual was updated, clarifying that genetic results cannot disqualify service-connected benefits and emphasizing the importance of clear communication during counseling.4

Significant improvements in median OS for de novo metastatic hormone sensitive PCa were observed in patients diagnosed between 2000 and 2019 in SEER and VHA databases. The gains were notable in patients younger than 70 years, likely driven by the increased adoption of combination therapies.6

Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
survey writer start date
Sun, 04/06/2025 - 17:18
Slide Media